Vasomotor rhinitis

Summary

Vasomotor rhinitis (MONDO:0006004) is a disease and 9 clinical trials. Top therapeutic interventions include azelastine, levocetirizine, and fluticasone furoate. A subtype of allergic rhinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vasomotor rhinitis
Mondo ID	MONDO:0006004
EFO	EFO:0007533
MeSH	D012223
DOID	DOID:4730
ICD-10-CM	J30.0
ICD-11	1286636442
NCIT	C34988
SNOMED CT	8229003
UMLS	C0035460
MedGen	11229
Is cancer (heuristic)	no

Disease family

This is a subtype of allergic rhinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › allergic respiratory disease › allergic rhinitis › vasomotor rhinitis

Related subtypes (2): seasonal allergic rhinitis, perennial allergic rhinitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Fluticasone Furoate	Phase 3 (in late-stage trials)
Levocetirizine	Phase 3 (in late-stage trials)
Pseudoephedrine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	4
Not specified	4
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00979615	PHASE4	COMPLETED	Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis
NCT00118703	PHASE3	COMPLETED	Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
NCT00682162	PHASE3	COMPLETED	Impact of Acupuncture on Vasomotor Rhinitis
NCT00976209	PHASE3	COMPLETED	Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)
NCT01509209	PHASE3	COMPLETED	Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis
NCT05348148	Not specified	RECRUITING	Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis
NCT00415493	Not specified	COMPLETED	Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation
NCT00745849	Not specified	COMPLETED	Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial
NCT07266688	Not specified	COMPLETED	Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AZELASTINE	4	3
LEVOCETIRIZINE	4	2
FLUTICASONE FUROATE	4	1
OLOPATADINE	4	1
PHENYLEPHRINE	4	1
PSEUDOEPHEDRINE	4	1